Research and development for biocompatibility testing, animal studies, and sterilization testing in the blueprint medtech (bpmt) initiative

Active Indefinite Delivery Contract Awarded Last action

Contract number
75N95023D00022
Awardee
Awarding agency
Task orders
5 $143,179 obligated

Award facts

Opportunity
Combined order value
  • $143,179 Current, with exercised options
  • $216,871 Potential, with all options
Last date to order 62% complete
IDV ceiling <1% used
$35,000,000.00
Award type
Single award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

The National Institute on Drug Abuse awarded an indefinite-delivery contract to Actuated Medical, Inc., a woman-owned small business, on September 20, 2023, with a $35 million ceiling through September 19, 2028, as a single-award vehicle supporting the Blueprint MedTech Initiative for biocompatibility testing, animal studies, and sterilization testing of emerging medical technologies focused on nervous system disorders.

Work is performed at Actuated Medical's facilities in Bellefonte, Pennsylvania. The originating solicitation, posted January 18, 2022, requested capabilities to provide biocompatibility assessment, good laboratory practice animal testing, sterilization validation, and shelf life testing in compliance with ISO 10993 and FDA guidance, including IACUC approval of protocols. NAICS 541715 (Research and Development in the Physical, Engineering, and Life Sciences, excluding Biotechnology) and PSC R425 apply.

The contract enables both cost-reimbursement and firm fixed-price delivery orders. Recent task orders include: a $3,777.48 cost-plus-fixed-fee order for kickoff meetings and FY26 UDO Initiative support (awarded September 20, 2023, completed September 19, 2024); an $81,702 cost-plus-fixed-fee order for five study protocol development reports (awarded November 22, 2023, completing November 21, 2028); a $32,848 firm fixed-price order for biocompatibility testing for Rhaeos (awarded July 14, 2025, completing January 13, 2026); a $32,848 cost-plus-fixed-fee order for biocompatibility testing for Neurastasis (awarded August 18, 2025, completing February 17, 2026); and a $65,696 cost-plus-fixed-fee order for Endovascular Horizons Testing (awarded August 18, 2025, completing February 17, 2026), all performed in Bellefonte, Pennsylvania.

Task orders

Transactions

Action Obligated Date
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $0

Quick answers

Who was awarded contract 75N95023D00022?

75N95023D00022 was awarded to Actuated Medical, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 20, 2023.

How much is contract 75N95023D00022 worth?

Orders under 75N95023D00022 have obligated $143,179. Their combined potential value, with all options, is $216,871. 75N95023D00022's own ceiling is $35,000,000.

How many orders have been placed under contract 75N95023D00022?

5 orders have been placed under 75N95023D00022, the latest on August 18, 2025.

Who can order from contract 75N95023D00022?

75N95023D00022 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract 75N95023D00022 competed?

The extent of competition for 75N95023D00022 was full and open competition. The government received 2 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV